statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Entera Bio (NASDAQ:ENTX - Get Free Report) and Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two...

Analyzing Entera Bio (NASDAQ:ENTX) and Lexeo Therapeutics (NASDAQ:LXEO)

Entera Bio Ltd. (NASDAQ:ENTX  Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 8,100 shares...

Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 523.1% in March

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Entera Bio announces key milestone for Oral PTH1-34 peptide

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ( Entera or the Company ), a leader in the development of orally delivered peptides, announced today that The American...

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Entera Bio announces PK data from oral GLP-2 peptide tablet treatment

Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean SE, n=15)

 Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean SE, n=15)

JERUSALEM, March 20, 2024 (GLOBE...

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio management to meet virtually with Oppenheimer

Entera Bio management to meet with Oppenheimer

Entera Bio GAAP EPS of -$0.31 beats by $0.01...

Entera Bio GAAP EPS of -$0.31 beats by $0.01

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Volume	163,385.00
52-Wk High	$3.35
52-Wk Low	$0.52

ENTX Entera Bio Ltd

About

Feed

News

Sentiment

Fundamentals